Fulcrum Therapeutics, Inc. (FULC)

Fulcrum Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	2.51	2.81	6.34	19.16	8.82	-
Revenue Growth (YoY)	-37.95%	-55.77%	-66.90%	117.19%	-	-
Cost of Revenue	74.86	71.8	76.78	69.7	59.04	71.07
Gross Profit	-72.35	-69	-70.44	-50.54	-50.22	-71.07
Selling, General & Admin	40.21	41.67	41.69	30.52	21.39	13.15
Operating Expenses	40.21	41.67	41.69	30.52	21.39	13.15
Operating Income	-112.56	-110.66	-112.13	-81.05	-71.61	-84.22
Interest & Investment Income	13.13	13.33	2.69	0.21	0.79	1.54
EBT Excluding Unusual Items	-99.43	-97.34	-109.44	-80.85	-70.82	-82.68
Merger & Restructuring Charges	-	-	-0.43	-	-	-
Pretax Income	-99.43	-97.34	-109.87	-80.85	-70.82	-82.68
Net Income	-99.43	-97.34	-109.87	-80.85	-70.82	-82.68
Preferred Dividends & Other Adjustments	-	-	-	-	-	7.13
Net Income to Common	-99.43	-97.34	-109.87	-80.85	-70.82	-89.81
Shares Outstanding (Basic)	62	61	45	35	25	11
Shares Outstanding (Diluted)	62	61	45	35	25	11
Shares Change (YoY)	24.35%	36.27%	27.23%	39.47%	129.53%	778.76%
EPS (Basic)	-1.61	-1.59	-2.44	-2.29	-2.79	-8.13
EPS (Diluted)	-1.61	-1.59	-2.44	-2.29	-2.79	-8.13
Free Cash Flow	-92.5	-91.47	-99.01	-80.19	-55	-40.43
Free Cash Flow Per Share	-1.49	-1.49	-2.20	-2.27	-2.17	-3.66
Gross Margin	-	-	-	-263.73%	-	-
Operating Margin	-4484.38%	-3945.24%	-1768.12%	-422.97%	-811.64%	-
Free Cash Flow Margin	-3685.18%	-3261.07%	-1561.23%	-418.47%	-623.34%	-
EBITDA	-110.47	-108.49	-109.72	-78.54	-69.23	-82.16
D&A For EBITDA	2.09	2.17	2.41	2.52	2.38	2.05
EBIT	-112.56	-110.66	-112.13	-81.05	-71.61	-84.22

Source: S&P Capital IQ. Standard template.